IMMUNE THERAPY INFLUENCE ON a-DEFENSIN LEVEL IN PERIPHERAL BLOOD NEUTROPHILES IN PYODERMIA PATIENTS

Background. The purpose was to investigate a-defensin levels in neutrophiles of pyodermia patients in comparisonwith healthy donors, to estimate clinical efficiency of glucosaminyl muramyl dipeptide (Licopid) and its influence on a-defensin levels.Materials and method. 31 patients with pyodermia and 17 healthy donors were investigated. Intracellular a-defensinlevels in neutrophiles in the peripheral blood were estimated by flow cytometry with mouse anti-NPantibodies (Hycult biotechnology). All patients with pyodermia were treated with Licopid 10 mg once a day within 10 days. Clinicaland laboratory results were measured after 7-0 days course of treatment and one month after treatment.Results. The a-defensin level in patients with pyodermia was reduced in comparison with healthy donors. Immunetherapy with licopid 10 mg once a day as a complex treatment lead to a-defensin level increase in leukocytesof peripheral blood.Conclusion. The treatment with licopid 10 mg a day lead to prolonged remission and to increase of endocellulara-defensin level. Definition of a-defensin levels can be useful for advisability and for selection of immunetherapy in pyodermia patients. Thus, a decrease of a-defensin levels in pyodermia patients, possibly, is a markerof the chronic bacterial inflammation.